A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd.’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are moving the once-daily, oral myeloid kinome inhibitor closer to registrational studies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?